Insight Molecular Diagnostics Inc. (IMDX)
US — Healthcare Sector
Automate Your Wheel Strategy on IMDX
With Tiblio's Option Bot, you can configure your own wheel strategy including IMDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMDX
- Rev/Share 0.1496
- Book/Share 0.3977
- PB 7.2671
- Debt/Equity 0.3404
- CurrentRatio 3.745
- ROIC -1.1247
- MktCap 82651977.0
- FreeCF/Share -0.8925
- PFCF -3.6044
- PE -1.2758
- Debt/Assets 0.0576
- DivYield 0
- ROE -7.6691
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Insight Molecular Diagnostics Inc. (IMDX)
- IPO Date 2015-12-30
- Website https://imdxinc.com
- Industry Biotechnology
- CEO Joshua Riggs
- Employees 46
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.